(lp0
S'Stock Alert and Holding Pattern: Intercept Pharmaceuticals Inc Price ... CML News - 17 hours ago Before we cover the full analysis we make a quick alert here that Intercept Pharmaceuticals Inc  has seen its stock price move at an amplified level.'
p1
aS"Intercept Pharmaceuticals Inc  Stock Could Be Biotech's Grand Slam Investorplace.com - Jan 24, 2017 The market has begun 2017 trading sideways, but don't let that fool you into thinking there aren't opportunities out there, especially in biotech."
p2
aS"This Analyst Bullish On Intercept Pharmaceuticals Inc  Long-Term Smarter Analyst - Feb 10, 2017 Intercept Pharmaceuticals Inc  shares rose as much as 9% during Friday's trading session, after the drug maker announced changes to its ongoing Ocaliva Phase 3 trial in NASH that increase probability of completing enrollment for interim&nbsp;...Intercept Pharma  to Provide Update on Phase 3 REGENERATE Trial of OCA ... - StreetInsider.comIs Intercept Pharmaceuticals Inc  Stock A Buy After OCA Update? - BNL Finance   "
p3
aS'Intercept Pharmaceuticals, Inc.  Recent Ownership Changes Post Analyst - Mar 16, 2017 Intercept Pharmaceuticals, Inc.  reached 30.26% versus a 1-year low price of $96.63. The stock was last seen 3.31% higher, reaching at $125.87 on Mar. 15, 2017.Intercept Pharmaceuticals Inc - Receive News &amp; Ratings Daily - BBNS'
p4
aS'Charles Payne on Biotech: Biogen Inc , Intercept Pharmaceuticals Inc  Investorplace.com - Nov 29, 2016 Still, I am not interested in chasing drug names, as most of the large pharmaceutical companies have thin product pipelines and aging blockbusters.'
p5
aS"Blog Coverage Intercept Pharmaceuticals Received NICE Approval for Ocaliva for ... Yahoo Finance - Mar 3, 2017 LONDON, UK / ACCESSWIRE / March 3, 2017 / Active Wall St. blog coverage looks at the headline from Intercept Pharmaceuticals, Inc.  as the Company announced on March 01, 2017, that UK's National Institute for Health and Care&nbsp;..."
p6
aS"Intercept Pharmaceuticals Reports Third Quarter 2016 Financial Results and ... GlobeNewswire  - Nov 3, 2016 NEW YORK, Nov. 03, 2016  -- Intercept Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today&nbsp;...Intercept Pharmaceuticals'  CEO Mark Pruzanski on Q3 2016 Results ... - Seeking Alpha"
p7
aS'Intercept Pharmaceuticals Inc.  Moves Higher on Volume Spike for February 13 Equities.com - Feb 13, 2017 Intercept Pharmaceuticals Inc.  traded on unusually high volume on Feb. 13, as the stock gained 3.47% to close at $122.62.The Top Three Holders Of Intercept Pharmaceuticals, Inc.  - Post AnalystLarge Outflow of Money Witnessed in Intercept Pharmaceuticals, Inc. - Highland Mirror'
p8
aS'Intercept Pharmaceuticals, Inc.  Valuation Review &amp; Update Business Review - Mar 17, 2017 Intercept Pharmaceuticals, Inc.  has an ERP5 rank of 15991. The ERP5 Rank is an investment tool that analysts use to discover undervalued companies.'
p9
aS'Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and ... GlobeNewswire  - Feb 23, 2017 NEW YORK, Feb. 23, 2017  -- Intercept Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today&nbsp;...Intercept Pharmaceuticals  Q4 2016 Results - Earnings Call Transcript - Seeking AlphaINTERCEPT PHARMACEUTICALS, INC.  Files An 8-K Results of ... - Market Exclusive'
p10
a.